Key result
In a rat model of high-output heart failure, acute inhibition of the angiotensin converting enzyme or angiotensin II type 1 receptors restored ANP release in response to volume expansion.
Why the study?
Does acute inhibition of the renin-angiotensin system restore ANP release and diuretic response to volume expansion in a rat model of high-output heart failure?
Does acute inhibition of the renin-angiotensin system restore ANP release and diuretic response to volume expansion in a rat model of high-output heart failure?
In a rat model of high-output heart failure, acute inhibition of the renin-angiotensin system restores the impaired ANP release and diuretic response to volume expansion, suggesting an additional mechanism for the benefits of these drugs in heart failure.
Answers are grounded in this paper and cite their sources.
Angiotensin inhibition may blunt ANP release to volume load in experimental HF; leaves open clinical relevance in patients.
OBJECTIVE: In heart failure atrial natriuretic peptide (ANP) release in response to volume expansion is impaired while the renin-angiotensin system is activated. This study was designed to test the hypothesis that ANP release in heart failure is dependent on an activated angiotensin system. METHODS: We studied the ANP and renin-angiotensin systems in a rat model of shunt-induced high-output heart failure, in which we rapidly increased circulating fluid volume with a 5 ml, hyperoncotic infusion, and evaluated the effects of acute inhibition of the angiotensin converting enzyme as well as of the blockade of the angiotensin II type 1 receptors on the ANP release and on renal excretory function. RESULTS: ANP and angiotensin II plasma concentrations prior to volume expansion were elevated (p < 0.05) in rats with aortocaval shunt compared to controls. The diuretic response to acute volume expansion (18.5 +/- 1.5 vs. 48.2 +/- 2.4 microliters/min, p < 0.001) was markedly blunted. ANP release was attenuated in rats with aortocaval shunt, as was the increase of its second messenger cGMP in plasma and urine. The blunted increase in ANP plasma levels was not due to depleted cardiac stores as cardiac ANP content, as well as ANP synthesis, were increased (p < 0.05). Acute inhibition of the angiotensin converting enzyme as well as blockade of the angiotensin II type 1 receptors restored ANP release in response to volume expansion (p < 0.01). Moreover, acute inhibition of the renin-angiotensin system completely normalized the diuretic response. CONCLUSIONS: Our data suggest that the ANP system is impaired in rats with aortocaval shunt. The activation of the angiotensin system contributes to the impairment of the ANP system. Acute inhibition of the angiotensin II system significantly improved the ability of the ANP system to respond to acute volume expansion. Our findings indicate a hitherto fore unappreciated interaction between both systems and suggest additional mechanisms for the beneficial effects of angiotensin converting enzyme inhibition or angiotensin II type 1 receptor antagonists in heart failure.
No takes yet. Share an insight, caveat, or question.
Roland Willenbrock (1999) studied Shunt-induced high-output heart failure. Acute inhibition of the angiotensin converting enzyme or angiotensin II type 1 receptors vs. Controls (rats without shunt or without inhibition) was evaluated on ANP release and renal excretory function in response to volume expansion (p=<0.01). In a rat model of high-output heart failure, acute inhibition of the angiotensin converting enzyme or angiotensin II type 1 receptors restored ANP release in response to volume expansion.
Synapse has enriched 10 related papers. Consider them for comparative context: